Genetically Modified DR5-Specific TRAIL Variant DR5-B Revealed Dual Antitumor and Protumoral Effect in Colon Cancer Xenografts and an Improved Pharmacokinetic Profile

Despite the weak clinical efficacy of TRAIL death receptor agonists, a search is under way for new agents that more efficiently activate apoptotic signaling. We previously created a TRAIL DR5-selective variant DR5-B without affinity for the DR4, DcR1, DcR2, and OPG receptors and increased proapoptot...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Anne V. Yagolovich, Artem A. Artykov, Tatiana A. Karmakova, Maria S. Vorontsova, Andrey A. Pankratov, Alexander A. Andreev-Andrievsky, Dmitry A. Dolgikh, Mikhail P. Kirpichnikov, Marine E. Gasparian
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Elsevier 2020-04-01
Saila:Translational Oncology
Sarrera elektronikoa:http://www.sciencedirect.com/science/article/pii/S1936523320300668
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak